Agenus Joins Rodman & Renshaw Fireside Chat to Discuss BOT+BAL Development

By Public Technologies
  • Agenus will participate in Rodman & Renshaw’s virtual fireside chat Nov. 5, 2026, from 11:30 a.m. to 12:30 p.m. ET.
  • Discussion will cover botensilimab and balstilimab development, including neoadjuvant colon cancer results and the planned Phase 3 ROBBIN trial.
  • Management will also discuss strategic priorities, funding and the commercial opportunity for the drug combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102477263) on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk